We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering speci... Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis. Show more
Rapidly enrolling patients in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathyAligned with FDA on design for a new Phase 3 trial...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...
Extended follow-up will include safety, kallikrein reduction and attack rate data, including number of patients who continue to be completely attack free through the latest follow-upIntellia to...
CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 2.35 | 10.0513259196 | 23.38 | 26.98 | 22.756 | 1596210 | 24.68715767 | CS |
4 | 3.79 | 17.2743846855 | 21.94 | 26.98 | 19.37 | 1309665 | 22.85541227 | CS |
12 | -1.27 | -4.7037037037 | 27 | 34.87 | 19.37 | 1465032 | 26.51039019 | CS |
26 | -0.95 | -3.56071964018 | 26.68 | 34.87 | 19.37 | 1496523 | 27.57086681 | CS |
52 | -17.83 | -40.9320477502 | 43.56 | 47.48 | 19.37 | 1252194 | 30.86480304 | CS |
156 | -39.8 | -60.7355409736 | 65.53 | 202.73 | 19.37 | 1232783 | 64.99185624 | CS |
260 | 10.41 | 67.9503916449 | 15.32 | 202.73 | 9.18 | 1108180 | 55.39797837 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions